πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 72 of 173

  1. US 9925181

    Biopolymer drug loading method

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9925157

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9925158

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9925172

    Compounds and methods for treating an epileptic disorder

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9925162

    Methods and compositions for inducing physiological hypertrophy

    Expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9919065

    Somatostatin analogs with inhibitory activity to growth hormone release

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9919055

    Sugar-linker-drug conjugates

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9918989

    Combination therapies for malaria

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9921223

    Analysis of genomic DNA, RNA, and proteins in exosomes for diagnosis and theranosis

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9919008

    Method for treating age-related hearing loss (ARHL)

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9918959

    TLR-independent small molecule adjuvants

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9918968

    Rapamycin analogs targeting proteasome function in the treatment of cancer

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9918983

    Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9920320

    Methods of modulating compliance of the trabecular meshwork

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9920100

    Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9915668

    Antibody based reagents that specifically recognize toxic oligomeric forms of tau

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9913900

    Method of treating alvelor bone loss through the use of anti-sclerostin antibodies

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9914775

    Methods for treating inflammatory disorders or cancer metastasis by administering antibodies to connexin 43 (Cx43) hemichannels

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9914774

    Notch pathway inhibition

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9914723

    Small molecule inhibitors of Mcl-1 and uses thereof

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9913820

    Antimicrobial compositions comprising glyceryl nitrates

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9909188

    Methods and compositions involving lincRNA and leukemia

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9908916

    Peptide for suppressing osteoclast differentiation and use thereof

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9908856

    Therapeutic compounds

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9907856

    Carboxymethylcellulose-peptide conjugates and methods for using the same

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9907762

    Stabilized mutant opsin proteins

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9907820

    Polyclonal gamma delta T cells for immunotherapy

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9902690

    Ethoxylated surfactants

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9902781

    Antibodies for botulinum neurotoxins

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9903855

    Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9901648

    Stabilization of biomolecules using sugar polymers

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9902713

    Neuroprotective compounds and use thereof

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9902780

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9895420

    IL-1beta propeptide and IL-1Ra chimera and methods of using the same

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9899614

    Phosphorescent tetradentate metal complexes having modified emission spectra

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9896561

    Dendritic macroporous hydrogels prepared by crystal templating

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9896532

    Deactivation of urushiol and method of treatment and prevention of contact dermatitis

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9896481

    Modified mini-hepcidin peptides and methods of using thereof

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9895454

    Metal oxide catalyzed radiofluorination

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9895429

    Antibodies that bind amyloid oligomers

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9896437

    Diarylhydantoin compounds

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9895414

    Inhibition of cancer growth and metastasis

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9895396

    Citrate containing beverage

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9895328

    Calcium formate as a supplement to prevent neural tube defects

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9895411

    Analogs of C5a and methods of using same

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9895413

    Protection against and treatment of ionizing radiation

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9895433

    Interferon-Ξ² production modulating listeria strains and methods for using same

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9895373

    Substituted pyrazolo[3,4-D]pyrimidines and uses thereof

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.